A new study published in the British Journal of Cancer suggests that the severity of bladder cancer can be detected by carrying out a simple urine test.
Researchers led by Dr Douglas Ward, from the University of Birmingham, studied over 600 patients suffering from varying grades of bladder cancer and analyzed their tumors, measuring the levels of a specific protein, EpCAM, shed by the tumors and found that higher levels of the protein in urine coincided with a more aggressive form of cancer.
Bladder Cancer
Bladder Cancer affects the urinary bladder and can be superficial or deep type and this affects its recurrence rate & prognosis.
Advertisement
The researchers hope that their findings will allow doctors to provide a more personalized treatment for patients depending on the severity of their cancers.
"This protein could be used to help doctors to decide what the best course of investigation or treatment for the patients is, and may prevent unnecessary delays. We've known for some time that the protein EpCAM is released from some tumor cells but it wasn't clear whether it would be useful as a way to decide the best investigation and treatment for patients suspected of having bladder cancer. We are now planning further studies to test the benefits of urine biomarker testing to patients and the NHS", Dr Ward said.
Source: Medindia
Source: Medindia
Gallbladder Cancer
Gallbladder cancer is a cancer that starts in the walls of the gallbladder. It is a rare form of tumor.
Advertisement
 Interstitial CystitisInterstitial cystistis is an umbrella term where a pathology cannot be defined but the patient suffers from recurring, pain in the pelvic region along with other symptoms including frequency or urgency in urination | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
A ray of hope for glioma patients as targeted therapy boosts treatment duration.